Humanetics

IN THE PRESS

BioMidwest

Humanetics Biomed expands its outsourced manufacturing capabilities to new markets

May 19, 2023

·

3 min read

Drug Development

ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment

April 12, 2023

·

2 min read

BioMidwest

ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial

March 8, 2023

·

3 min read

Drug Development

Humanetics Corporation Announces Positive Results from Independent Data Monitoring Committee Review of Phase 2 Clinical Trial

February 15, 2023

·

2 min read

BioMidwest

ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference

February 2, 2023

·

1 min read

BioMidwest

ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research

January 26, 2023

·

2 min read

BioMidwest

Humanetics Corporation Presents at the MedInvest Oncology Investor Conference

December 16, 2022

·

2 min read

Drug Development

Humanetics Corporation Publishes Phase 1 Trial Results for BIO 300 Oral Powder

November 15, 2022

·

2 min read

BioMidwest

Humanetics Corporation Presents at the 68th Annual International Radiation Research Society Meeting

October 25, 2022

·

2 min read

FDA

Humanetics Receives FDA Clearance to Begin Studies in Second Oncology Indication

October 5, 2022

·

2 min read

JOBS